Table 3.

Number of patients with TEAEs by treatment

	Number (%) of patients
	Vericiguat + nitroglycerin (n = 24)	Placebo + nitroglycerin (n = 12)
Any TEAE, n (%)	22 (91.7)	11 (91.7)
Any vericiguat‐related TEAE a	11 (45.8)	5 (41.7)
Any nitroglycerin‐related TEAE a	7 (29.2)	5 (41.7)
Any TEAE related to study procedures a	3 (12.5)	1 (8.3)
TEAE‐related deaths, n (%)	0 (0.0)	0 (0.0)
Any SAEs, n (%)	2 (8.3)	1 (8.3)

SAE, serious adverse event; TEAE, treatment‐emergent adverse event.

^a Relationship was assigned by the investigator (under double‐blind conditions) according to the most plausible cause.